Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Actual GLP-1 acquisition creative; peptide/sermorelin keyword searches showed no matches. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A long care page develops a direct offer through product quality, treatment comparisons, care steps, customer stories and assessment entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
This is the cleanest of Eden's price statics because every number agrees: the creative, the ad headline and the copy all say $129, so the viewer never has to reconcile two prices. The headline is conversational and a little cheeky, which makes a price ad feel like someone talking rather than a rate card. Underneath, the fee list does the proof work by showing line items that come to nothing extra, and three vials make the medication the subject of the image. The copy adds the 200,000+ customer line, which gives a stranger a reason to trust the price.
The ad never says what the $500 is. Without a source (another provider, a typical cash price, a brand-name pen), the viewer has to take the comparison on faith, and a skeptical price shopper is exactly the person this ad targets. Name what the $500 refers to in small type under the headline, using a figure you can stand behind. There's also no reason to act now; the lifetime price guarantee shown on the landing page would turn a good price into a price you can keep, which is a stronger close.
It frames the price as the reasonable choice before the viewer has formed their own anchor.
The list answers the follow-up question (what's included?) and the vials show what the money buys.
It adds social proof and the care promise to a creative that's otherwise all price.
$129 a month for compounded tirzepatide, framed against an unnamed $500 price, with no hidden fees and cancel anytime.
The click lands on Eden's GLP-1 affiliate page, a focused landing page built around the monthly price. The hero lists tirzepatide at $129/mo right next to semaglutide at $99/mo, so this ad's number shows up immediately, and the same 200,000+ member line appears as a Trustpilot badge at the top right. The free assessment button (takes 3 minutes, no insurance needed) gives the next step, and the treatment comparison and plan inclusions sections further down explain what sits behind the price. It's a strong match for a price-led ad.
Eden's GLP-1 affiliate page is a long, focused landing page that opens on semaglutide at $99/mo and tirzepatide at $129/mo with a free assessment, then covers quality, treatment, care steps, stories and FAQs. All 16 Eden ads in the Fluid library link here, mostly price comparisons plus creator and doctor videos.
The headline, three benefits, both monthly prices and the free assessment button answer what it costs and how to start, with Trustpilot and member-count proof alongside.
It covers where the medication comes from and who oversees care, answering whether a low price means cutting corners.
It explains the problem and how the treatment is meant to work, answering why someone would consider it at all.
It compares treatment options so the visitor can work out which one fits before starting the assessment.
It walks through the steps from assessment to ongoing care, answering what happens after the click.
It shows stories from customers, answering whether people like the visitor have used the service.
It lists what the plan includes and repeats the assessment entry, answering what the monthly price covers right before asking again.
It handles remaining questions and the safety and compounding disclosures, answering the last objections before signing up.
Read the full breakdown of this page
One of 16 Eden ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.